Genmab A (GMAB) Current Deferred Revenue (2023 - 2025)
Genmab A's Current Deferred Revenue history spans 3 years, with the latest figure at $24.0 million for Q4 2025.
- For Q4 2025, Current Deferred Revenue rose 700.0% year-over-year to $24.0 million; the TTM value through Dec 2025 reached $24.0 million, up 700.0%, while the annual FY2025 figure was $24.0 million, 700.0% up from the prior year.
- Current Deferred Revenue reached $24.0 million in Q4 2025 per GMAB's latest filing, up from $3.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $24.0 million in Q4 2025 to a low of $3.0 million in Q4 2024.
- Average Current Deferred Revenue over 3 years is $10.7 million, with a median of $5.0 million recorded in 2023.
- Peak YoY movement for Current Deferred Revenue: plummeted 40.0% in 2024, then surged 700.0% in 2025.
- A 3-year view of Current Deferred Revenue shows it stood at $5.0 million in 2023, then tumbled by 40.0% to $3.0 million in 2024, then soared by 700.0% to $24.0 million in 2025.
- Per Business Quant, the three most recent readings for GMAB's Current Deferred Revenue are $24.0 million (Q4 2025), $3.0 million (Q4 2024), and $5.0 million (Q4 2023).